By the same token, it would be a waste for the FDA to require a phase 3 study for mild & moderate if the severe & critical phase 3 comes back with gangbusters results. Odds are about 99.9999% we hear nothing from the FDA on the Covid front until the interim data is in. Same for MHRA; these meetings are pre-planning in the event severe & critical data is as solid as we expect.

If that turns out to be the case, everything will be happening at once.